Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of organic compounds known as 1-benzoylpiperidines. It features a piperidine ring substituted with a benzoyl group that is further modified by a (2,4-diaminopteridin-6-yl)methyl(methyl)amino moiety and an esterified carboxylic acid at the piperidine's fourth position. The structure is related to antifolate agents and pteridine derivatives but does not correspond to any approved pharmaceutical drug or widely recognized clinical candidate. Its mechanism of action has not been explicitly described in public databases; however, structurally similar compounds often act as inhibitors of folate-dependent enzymes such as dihydrofolate reductase or pteridine reductase. This compound appears in chemical and experimental drug databases but lacks evidence for clinical development or therapeutic use[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)piperidine-4-carboxylate.